For BMS, the data positions CC-486 into a segment of the AML market that for the time being sidesteps competition from Venclexta and other drugs coming through the pipeline like Roche’s MDM2 ...

AbbVie’s oncology segment generated combined revenues of $3.3 billion in the first half of 2025, rising 4.2% year over year ...

Data from the study published in the New England Journal of Medicine in February showed that 77% of patients treated with Calquence plus Venclexta and 83% of patients treated with Calquence ...

AbbVie’s ABBV stock has risen 11.5% in the past month, mainly due to its beat-and-raise performance in the second quarter.

Intensive chemotherapy improved survival in patients with accelerated and blast phase myeloproliferative neoplasms, with ...

Discover AbbVie's standout Q2 2025 earnings insights, with strong Skyrizi & Rinvoq growth, raised revenue guidance, and robust R&D progress driving future ...

AbbVie said on Thursday its tariff exposure is not expected to exceed that of rivals, and raised its 2025 profit forecast citing strong sales of its newer immunology drugs Skyrizi and Rinvoq.

Its cancer drug Venclexta, which brought in $691 million in sales during the quarter, is expected to benefit from Trump's "one big beautiful bill".

The submission is based on the positive results from the Phase 3 AMPLIFY trial. The combination regimen of VENCLEXTA and acalabrutinib improved progression-free survival (PFS) compared to standard ...